title: Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.
abstract: Described here is the case of a patient with infective endocarditis in a prosthetic valve due to a Mycobacterium fortuitum-group organism. The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacterium fortuitum-group endocarditis, and the first of survival without surgical intervention. The duration of treatment is not well defined for this patient, but life-long suppressive therapy will likely be required.
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Kunin
authors.forename: F
authors.initials: F
authors.lastname: Salamon
authors.forename: M
authors.initials: M
authors.lastname: Weinberger
authors.forename: I
authors.initials: I
authors.lastname: Genkin
authors.forename: A
authors.initials: A
authors.lastname: Sagie
authors.forename: R
authors.initials: R
authors.lastname: Tur-Kaspa
mesh_terms: D000368:Aged; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D006350:Heart Valve Prosthesis / Q000382:microbiology*; D006801:Humans; D008297:Male; D000077731:Meropenem; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000382:microbiology; D019907:Mycobacterium fortuitum / Q000302:isolation & purification*; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology*; D013845:Thienamycins / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002939:Ciprofloxacin; D000583:Amikacin; D000077731:Meropenem